Aug 26, 2025
VG801 receives regenerative medicine advanced therapy designation for Stargardt disease
By: Alex Young Fact checked by : Christine Klimanskis, ELS Key takeaways: VG801 is a dual-AAV gene therapy in development for …
Resources
Aug 15, 2025
What the eyes reveal: Cardiovascular clues in women—hidden in plain sight
Author(s): Lynda Charters Fact checked by: Karen S. DeLoss, OD, FAAO Key Takeaways Ocular exams can reveal cardiovascular health issues, …
Aug 12, 2025
Cosmetic procedures associated with serious ophthalmologic complications
Author(s): Lynda Charters Key Takeaways Minimally invasive cosmetic procedures can cause rare but severe ophthalmological complications, including irreversible vision loss …
Aug 11, 2025
EyePoint completes enrollment in second phase 3 trial of sustained-release AMD therapy
ByJay S. Duker, MD ByAlex Young ByAnthony DeFino Fact checked by Christine Klimanskis, ELS Key takeaways: More than 400 patients …
Aug 11, 2025
This common fruit has over 1,600 compounds that boost brain, heart, and gut health
Published August 6, 2025 | Originally published on ScienceDaily Top Health A new article appearing in the current issue of the peer-reviewed Journal of …
Aug 6, 2025
Study supports Iluvien as ‘long-acting option’ in diabetic macular edema
Key takeaways: The NEW DAY study did not meet its primary endpoint but showed good outcomes in secondary endpoints. A …
Aug 5, 2025
Geographic Atrophy Patient Experience Research
A new study is being conducted on geographic atrophy. They would like to hear about your experience with the drug …
Jul 31, 2025
Phase 3 study of LUMIFY Preservative Free and LUMIFY eye drops meets primary end point
Author(s): Jordana Joy Key Takeaways LUMIFY Preservative Free eye drops are statistically non-inferior to LUMIFY in reducing ocular redness, with …
Jul 28, 2025
VA-developed RainDrop Dispenser Aid aims to simplify use of single-use eye drops for patients with arthritis, tremors July 24, 2025
July 24, 2025 by Lynda Charters, Jordana Joy, Associate Editor Rain Eye Drops LLC announced the launch of a newly …
Jul 24, 2025
Novel AI-powered retina tracker detects eye disease in under one second
By: The Endocrine Society A novel AI-powered retina tracker can analyze retinal images with near-perfect accuracy in under one second, according …
Jul 24, 2025
Oral danegaptide for diabetic retinopathy successfully completes phase 1b trial
By: Justin Cooper Fact checked by: Christine Klimanskis, ELS Key takeaways: Danegaptide could be an oral therapy for patients with …
Jul 24, 2025
Survey finds majority of US patients delaying eye care despite experiencing poor eyesight, eye health
By: Jordana Joy, Associate Editor Survey participants cited cost concerns, perceived inevitability, and deprioritization as obstacles to receiving eye care.
Jul 24, 2025
FDA fast tracks one-time intravitreal gene therapy for geographic atrophy
By: Anthony DeFino Fact checked by: Christine Klimanskis, ELS Key takeaways: SAR446597 is designed to inhibit C1s and factor Bb …
Jul 8, 2025
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD
Author(s): Martin David Harp Key Takeaways Alcon’s acquisition of LumiThera includes a PBM device for early and intermediate dry AMD, …
Jul 8, 2025
Can you eye doctor predict an impending stroke?
A university study shows certain types of retina problems are early signs of stroke. Research scientists from the University of …
Jul 3, 2025
Happy Independence Day
The Macular Degeneration Association would like to wish everyone a safe and excellent 4th of July. The offices …
Jun 30, 2025
36-month results from phase 1/2a clinical study of RG6501 released
Author(s): Kassi Filkins Key Takeaways RG6501 (OpRegen) cell therapy shows sustained visual acuity and retinal structure improvements in GA patients …
Jun 30, 2025
Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3
Author(s): Glenn Yiu, MD, PhD Fact checked by: Sheryl Stevenson Frequent intravitreal injections for neovascular age-related macular degeneration present a …
Jun 23, 2025
Instant coffee can cause blindness, says report
Published in Food Science & Nutrition, the study examined a large genetic dataset of more than 5,00,000 people and used …
Jun 19, 2025
ILYX-002 rapidly improves immune-mediated dry eye disease in phase 2 trial
By Justin Cooper Fact checked by Christine Klimanskis, ELS Key takeaways: Dry eye disease associated with systemic autoimmune or inflammatory …
Jun 16, 2025
Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Author(s): Christine Curcio, PhD, Sheryl Stevenson Conferences|International SPECTRALIS Symposium – and Beyond From basal laminar deposits to foveal centering, a …
Jun 16, 2025
Cataract surgery may curb dementia, Alzheimer’s risk in those without anxiety, depression
By Justin Cooper Fact checked by Christine Klimanskis, ELS Key takeaways: Cataract surgery had a protective effect against overall dementia …
Jun 16, 2025
Undiagnosed AMD prevalence in urban setting higher than national average
By Alex Young Fact checked by Eamon N. Dreisbach Key takeaways: A hospital in New York had a higher percentage …
Jun 12, 2025
FDA nod for acoltremon: What its approval means for clinicians and patients
Author(s): Sheryl Stevenson Alcon’s announcement of the FDA approval for its acoltremon ophthalmic solution 0.003% (Tryptyr; formerly AR-15512) for the …
Jun 10, 2025
Press Release PAO Action Week
Press Release Hello, The Macular Degeneration Association is one of the 1,200+ patient advocacy organizations (PAOs) in the United …
Jun 10, 2025
Home OCT a ‘safety net’ for reducing treatment burden in wet AMD
ByAnthony DeFino Fact checked byChristine Klimanskis, ELS Key takeaways: Home OCT may help patients achieve extended dosing intervals through consistent …
Jun 2, 2025
Stop Smoking Now to Protect Your Vision, Experts Warn
Edited by Shrabasti Bhattacharya TOPLINE: Current smokers faced up to 12-fold higher risk for age-related macular degeneration, a threefold higher …
May 27, 2025
Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap
Author(s): Emily Kaiser Maharjan Key Takeaways Aldeyra’s phase 3 trial of reproxalap showed statistical superiority in reducing ocular discomfort compared …
May 26, 2025
Remember and Honor Our Fallen Heroes
“Their sacrifice was the ultimate act of love for their country. May we always remember them.” — Unknown
May 16, 2025
PARTICIPATE IN A MARKET RESEARCH STUDY ON VISUAL IMPAIRMENTS
Exafield US, a healthcare market research company based in the USA, is conducting a study on visual impairments and would …